RxDoctor Payments Data

Frances Andriacchi

Olympia, WANPI 1578638979

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 26.1% of the total. Reporting peaked in 2020 at $642 and has fallen 81.6% since, to $118 in 2022.

$1,664in general payments, 2019–2025

Across 111 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$435
  • Lilly USA, LLC$258
  • AbbVie$253
  • Xeris Pharmaceuticals, Inc.$161
  • Boehringer Ingelheim$118
  • Sanofi-aventis U.S. LLC$49
  • plus $390 from 15 others

What the payments were for

  • Food & beverage$1,664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →